Stifel Nicolaus cut shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a hold rating in a report issued ...

European stock markets closed at or near record highs on March 3 as economic data showed inflation continuing to decline across the continent, ...

Novo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its ...

A medical device company has secured investment from the owner of the developer of Ozempic and a private equity firm, to ...

Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs ...

Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload ...

Analysis of Aspen Pharmacare's H1 2025 results. Revenue up, EBITDA strong, focus on GLP-1s & sterile manufacturing. Learn ...

Novo Holdings and TA Associates ("TA"), announced today that the parties have entered into an agreement for Novo Holdings to ...

Stifel downgraded Novo Nordisk (NVO) to Hold from Buy with a price target of DKK 700, down from DKK 780. Novo is “no longer the same stock that ...

Novo Holdings and TA Associates have agreed to make an investment into Biocomposites.